SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening

• Main Authors: Delgado, Renee, Vishwakarma, Jyoti, Moghadasi, Seyed Arad, Otsuka, Yuka, Shumate, Justin, Cuell, Ashley, Tansiongco, Megan, Cooley, Christina B., Chen, Yanjun, Dabrowska, Agnieszka, Basu, Rahul, Anindita, Paulina Duhita, Luo, Dahai, Dosa, Peter I., Harki, Daniel A., Bannister, Thomas, Scampavia, Louis, Spicer, Timothy P., Harris, Reuben S.
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2024
• Subjects: Medicine, Health and Life Sciences; Antiviral drugs; Cell-based ultra-high throughput screening
• Online Access: https://hdl.handle.net/10356/181907
• Institution: Nanyang Technological University

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2, SARS2) is responsible for the COVID-19 pandemic and infections that continue to affect the lives of millions of people worldwide, especially those who are older and/or immunocompromised. The SARS2 main protease enzyme, Mpro (also called 3C...